all report title image
  • Published On : Mar 2022
  • Code : CMI4959
  • Industry : Pharmaceutical
  • Pages : 175
  • Formats :

Wilson’s disease is a rare genetic disorder characterized by excess copper stored in various body tissues, particularly in the liver, brain, and corneas of the eyes. The disease is progressive, and if left untreated, it may cause liver (hepatic) disease, central nervous system dysfunction, and death. The signs and symptoms of Wilson’s disease usually first appear between the ages of 6 and 45 years; however, they most often begin during the teenage years. Wilson’s disease is also known as hepatolenticular degeneration and lenticular degeneration. Early diagnosis and treatment prevent serious long-term disability and life-threatening complications. According to the National Organization for Rare Disorders, Inc. (NORD), Wilson’s disease is a rare disorder that affects males and females in equal numbers. The disease is found in all races and ethnic groups. The estimates vary; however, it is believed that Wilson’s disease occurs in approximately one in 30,000 to 40,000 people worldwide, according to NORD.

Colombia, Chile and Peru Wilson’s Disease Treatment Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has negatively impacted the growth of Colombia, Chile and Peru Wilson’s disease treatment market. Treatment for Wilson’s disease should be taken daily and continued lifelong. A patient needs to visit hospitals for the clinical examination, ultrasound of the liver, and urine samples every six months in the maintenance phase of the disease. The patient also needs to visit more frequently to the hospital when the treatment is just initiated. Due to the COVID-19 pandemic, government of respective countries imposed the lockdown on the entire nations respectively. This lockdown affected the treatments of many patients with diseases, including patients with Wilson's disease. The non-urgent care of these patients was therefore suspended. Medical consultations and paramedical care (physiotherapy, speech therapy, psychologist, etc.) have been postponed. Only urgent hospitalizations in the event of imbalance of patients’ illness with life-threatening risk were maintained. In this situation, Wilson's disease patients could be particularly anxious.

Moreover, due to the lockdown, the recruitment for clinical trials for overall diseases was halted. Thus, the COVID-19 has negatively impacted Colombia, Chile and Peru Wilson’s disease treatment market.

The increasing number of research and development activities to treat Wilson’s disease is expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market over the forecast period. For instance, in September 2017, according to The Wilson Disease Association, patients with Wilson’s disease were being recruited by Wilson Disease Association, for a Pilot study to evaluate brain changes using magnetic resonance imaging (MRI). The study was sponsored by The Wilson Disease Association.

Colombia, Chile and Peru Wilson’s disease treatment market is estimated to be valued at US$ 799.4 thousand in 2022 and expected to exhibit a CAGR of 5.1% over the forecast period (2022-2030).

Figure 1: Colombia, Chile and Peru Wilson’s Disease Treatment Market Share (%) Analysis, By Drugs, 2021

Colombia, Chile and Peru Wilson's Disease Treatment  | Coherent Market Insights

The increasing number of generic drug launches by the market players is expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market over the forecast period.

Market players are focused on organic growth strategies such as drug launches, which is expected to drive the market growth over the forecast period. For instance, in February 2018, Teva Pharmaceutical Industries Ltd., a pharmaceutical company, announced the launch of generic version of Syprine (trientine hydrochloride) capsules, 250 mg, in the U.S. Trientine hydrochloride is used in the treatment of patients with Wilson’s disease who are intolerant of penicillamine.

CMI table icon

Colombia, Chile and Peru Wilson’s Disease Treatment Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022:

US$ 799.4 K

Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 5.1% 2030 Value Projection:

US$ 1,190.2 K

Geographies covered:
  • Colombia
  • Chile
  • Peru
Segments covered:
  • By Drugs: D- Penicillamine, Trientine, Zinc Acetate
  • By Distribution Channel: Hospital Pharmacies, Government Distribution Channels
Companies covered:

Teva Pharmaceuticals Industries Ltd., Bausch Health Companies Inc., Alexion Pharmaceutical, Inc., and Sanofi S.A.

Growth Drivers:
  • The increasing number of generic drug launches
  • The increasing number of drug approvals from regulatory bodies
Restraints & Challenges:
  • High price of drugs and lack of proper regulatory policies

The increasing number of drug approvals from regulatory bodies is expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market over the forecast period.

Increasing approvals from regulatory authorities are expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market over the forecast period. For instance, in May 2019, Amerigen Pharmaceuticals Limited., a generic pharmaceutical company, announced that Amerigen's Abbreviated New Drug Application (ANDA) for Penicillamine Capsules USP 250 mg has received final approval from the U.S. Food and Drug Administration (FDA). This is the first such ANDA to be approved as a generic equivalent to Bausch Heath's Cuprimine.

Colombia, Chile and Peru Wilson’s Disease Treatment Market – Restraints

The high price of drugs (including branded and generic) for the treatment of Wilson’s disease and low affordability among patients for such drugs in Colombia, Chile, and Peru is a major hurdle for the market growth. For instance, in 2018, Teva Pharmaceutical Industries Ltd., a pharmaceutical company, launched the generic version of Syprine (branded drug for Wilson disease) in the U.S., which costs US$ 18,275 for 100 pills, a cheaper alternative to treat Wilson’s disease by less than US$ 3,000. However, this price is too high for patients in countries such as Chile, Colombia, and Peru. Thus, the launch of low price generics can increase the affordability for treatment among the population in these countries.

The lack of proper regulatory policies is also one of the major restraining factors for the market growth in Colombia, Chile, and Peru. For instance, in 2016, Latin American countries collaborated with the Pan American Health Organization (PAHO), which recognized Colombia to have national regulatory agencies that are competent and performant. However, despite this recognition of progress, the duration required to obtain product approval is relatively slow in the country. Therefore, no approvals of drugs from regulatory bodies abstain patients from treatments of rare diseases such as Wilson’s disease.

Colombia, Chile and Peru Wilson’s Disease Treatment Market – Country Analysis

On the basis of country, Colombia, Chile and Peru Wilson’s disease treatment market is segmented into Colombia, Chile, and Peru.

Colombia is expected to hold a dominant position in the market during the forecast period, owing to increasing expenditure on healthcare by the government. For instance, according to the report of World Data Atlas, in 2018, health expenditure per capita for Colombia was US$ 513. Health expenditure per capita of Colombia increased from US$ 158 in 2004 to US$ 513 in 2018, growing at an average annual rate of 9.62%.

Figure 2: Colombia, Chile and Peru Wilson’s Disease Treatment Market (US$ Thousand), by Country, 2021

Colombia, Chile and Peru Wilson's Disease Treatment  | Coherent Market Insights

Colombia, Chile and Peru Wilson’s Disease Treatment Market – Competitive Landscape

Major players operating in Colombia, Chile and Peru Wilson’s disease treatment market include Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Alexion Pharmaceutical, Inc., and Sanofi S.A.

Wilson’s disease is a rare genetic disorder characterized by excess copper stored in various body tissues, particularly in the liver, brain, and corneas of the eyes. The body needs a small amount of copper from food to be healthy, but excess copper is harmful. If Wilson’s disease is not treated it may lead to organ damage. Wilson’s disease is present in a person from birth; however, the symptoms don’t appear until the level of copper rises up the liver, the brain, or the other organs. The symptoms are related to the liver, nervous system and mental health, eyes, or other organs. Wilson’s disease develops symptoms related to the liver, such as hepatitis and inflammation of the liver. Nervous system and mental health symptoms include difficulty in speaking, stiff muscles, anxiety, and depression. Wilson’s disease is caused due to the mutation of the ATP7B gene. These gene mutations prevent the body from removing extra copper.

Market Dynamics

The increasing number of clinical trials by market players is expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market during the forecast period. For instance, Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca Plc., started a clinical trial of drug: ALXN1840, indicated for the treatment of Wilson’s disease. The study started in October 2021 and is expected to end in May 2024. The study is in Phase III.

Increasing inorganic growth strategies such as partnerships of pharmaceutical companies with local distributors for the distribution of medicines in the Peru is expected to drive the growth of Colombia, Peru and Chile Wilson’s disease treatment market. For instance, according to the International Trade Administration data of 2018, the U.S is the largest exporter of healthcare goods and services to Peru at 21.7% market share. This makes U.S. manufacturers to maintain good relations with local distributors, to provide after- sales services for medical devices.

Key features of the study:

  • This report provides an in-depth analysis of Colombia, Chile and Peru Wilson’s disease treatment market, market size (US$ Thousand), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in Colombia, Chile and Peru Wilson’s treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Alexion Pharmaceutical, Inc., and SanofiA.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
  • The Colombia, Chile and Peru Wilson’s treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing Colombia, Chile and Peru Wilson’s disease treatment

Detailed Segmentation:

  • Colombia, Chile and Peru Wilson’s Disease Treatment Market, By Drugs:
    • D- Penicillamine
    • Trientine
    • Zinc Acetate
  • Colombia, Chile and Peru Wilson’s Disease Treatment Market, By Distribution Channel :
    • Hospital Pharmacies
    • Government Distribution Channel
  • Colombia, Chile and Peru Wilson’s Disease Treatment Market, By Country:
    • Colombia
    • Chile
    • Peru
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Bausch Health Companies Inc.
    • Alexion Pharmaceutical, Inc.
    • Sanofi S.A.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Colombia, Chile and Peru Wilson’s disease treatment market is expected to exhibit a CAGR of 5.1% during the forecast period (2022-2030).
Ther market is estimated to be valued at US$ 799.4 Thousand in 2022.
Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Alexion Pharmaceutical, Inc., and Sanofi S.A., are some of the prominent players operating in the market.
The market is expected to be valued at US$ 1,190.2 Thousand in 2030.
Colombia is the prominent country in the market.
D- Penicillamine, which belongs to the drugs segment, is the prominent segment in the market.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo